Drugs / GR2002
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06175143 | Dec 2023 → Oct 2024 | atopic eczema | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05954611 | Jun 2023 → Jan 2024 | asthma | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GR2002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06175143 ↗ |
| Modality | Monoclonal antibody | “TSLP monoclonal antibody” NCT06175143 ↗ |
| Route | Subcutaneous | “single subcutaneous administration of GR2002 injection” NCT05954611 ↗ |
| Target | TSLP | “TSLP monoclonal antibody” NCT06175143 ↗ |